Premium
P1‐108: Plasma MCP‐1 is associated with a faster decline of cognitive function in MCI and dementia due to Alzheimer's disease
Author(s) -
Fuh Jong-Ling,
Lee Wei-Ju,
Liao Yi-Chu,
Wang Shuu-Jiun
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.06.306
Subject(s) - dementia , medicine , neuropsychology , neuroinflammation , disease , cognitive impairment , pathophysiology , cognitive decline , cognition , gastroenterology , psychiatry
Background:The ROSAS study is a monocentric observational study performed in Toulouse, France, designed to evaluate clinical evolution, and identify biochemical and imaging biomarkers of Alzheimer Disease Progression. 3 groups of participants were enrolled and followed up to 4 years: control participants (NC); patients with memory impairment without dementia (MCI) and patients with dementia of Alzheimer type (AD). In this work baseline characteristics of this cohort are presented. Their cognitive evolution, disease progression and behavioral changes are assessed. Methods: 408 subjects 65 years and older were enrolled, including 110 NC (MMSE 26 and CDR1⁄40), 100 MCI (MMSE 24 and CDR1⁄40.5, memory impairment RAVLT; but not DSM IV criteria for AD) and 196 AD (12 MMSE 26 and CDR 0.5; DSM IV criteria). Clinical examination, cognitive and behavioral evaluation (MMSE, NPI, ADAS Cog, CDR, RAVLT, ADCS-MCI-ADL), laboratory assessment of blood, urine and CSF were performed every 6 months. Results: Demographic analysis showed no gender difference in NC and MCI groups, while in AD patients there were twice more women. Concomitant pathologies were analyzed, only significant difference was observed for depression reported in 36% of MCI and 37.4% of AD patients. For longitudinal evaluations participants were divided into several groups: stable and progressing for NC and MCI; mild and moderate for AD. All MCI participants performed similarly in the beginning of the study (MMSE 26.262.0; ADAS Cog 961.2), however at 12 months visit, division into two groups occurred. Stable MCI kept similar scores to the end of the study, while the MCI progressors showed profiles similar to mild AD patients (Figures 1 and 2). Surprisingly, when AD patients were analyzed, independently on mild or moderate stages, 5 different clusters of decline were identified based on MMSE changes during 48 months: stable patients, three different types of slow decliners and rapid decliners. Differences between these groups are being now correlated with patients’ performance in other tests, blood and urine analysis and brain atrophy fromMRI. Conclusions: The ROSAS is a unique French monocentric cohort of long duration follow up, providing numerous possibilities for the exploration of AD biomarkers and multi-variant analysis of clinical evolution. P1-108 PLASMA MCP-1 IS ASSOCIATED WITH A FASTER DECLINE OF COGNITIVE FUNCTION IN MCI AND DEMENTIA DUE TO ALZHEIMER’S DISEASE Jong-Ling Fuh, Wei-Ju Lee, Yi-Chu Liao, Shuu-Jiun Wang, Taipei Veterans General Hospital, Taipei, Taiwan; National Yang-Ming University Schools of Medicine, Taipei, Taiwan; Taichung Veterans General Hospital, Taichung, Taiwan. Contact e-mail: jlfuh@vghtpe.gov.tw